(Q53145586)

English

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.

scientific article published on 18 September 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

Linda-Gail Bekker

6

object named as

Linda-Gail Bekker

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

Jose R. Arribas

object named as

Jose R Arribas

10

0 references

Christine Katlama

8

object named as

Christine Katlama

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

1

object named as

Joseph J Eron

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

Jürgen Rockstroh

2

object named as

Jürgen K Rockstroh

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

author name string

Jacques Reynes

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

Jaime Andrade-Villanueva

4

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

Jose Valdez Ramalho-Madruga

5

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

Benjamin Young

7

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

Jose Maria Gatell-Artigas

9

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

Mark Nelson

11

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

Havilland Campbell

12

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

Jing Zhao

13

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

Anthony J Rodgers

14

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

Matthew L Rizk

15

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

Larissa Wenning

16

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

Michael D Miller

17

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

Daria Hazuda

18

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

Mark J DiNubile

19

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

Randi Leavitt

20

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

Robin Isaacs

21

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

Michael N Robertson

22

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

Peter Sklar

23

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

Bach-Yen Nguyen

24

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

QDMRK Investigators

25

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

publication date

18 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

Lancet Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

11

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

12

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

907-915

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970196-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970196-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970196-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970196-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Raltegravir with optimized background therapy for resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970196-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970196-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970196-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970196-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970196-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970196-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Lack of a significant drug interaction between raltegravir and tenofovir.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970196-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970196-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970196-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE st

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970196-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970196-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative analysis of two rates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970196-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Initial treatment for HIV infection--an embarrassment of riches

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970196-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970196-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970196-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970196-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970196-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970196-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970196-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970196-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1473-3099(11)70196-7

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21933752

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53145586&oldid=1584883132"